doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,1,Monitoring evaluation,Suggested frequency,
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,2,Evaluation by clinician and monitoring for AEs,"During the first 2 months of treatment : Every day during the first weeks if the patient is hospitalized (e.g. for life-threatening conditions or severe comorbidities) and, where possible, at least on a weekly basis if the person is treated as an outpatient, until the treatment is well tolerated. Once the person is stable, a monthly visit is suggested. After the second month of treatment : Monthly assessments unless there is a medical necessity to see the patient more often. The treatment supporter sees the patient daily between consultations and signals any concerns to the clinician. VST will allow continuous monitoring. For monitoring for AEs : Daily at every encounter by the treatment supporter, or when possible when performing VST.",
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,3,Sputum smears and culture,"Monitoring smears and culture important after the second month of treatment (during hospitalization, can be done more often). Culture can be done monthly if feasible. It is important to perform culture at the end of treatment.",
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,4,Chest radiograph,"At baseline, after the second month of treatment and at the end of treatment, except where clinical needs suggest a higher frequency.",
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,5,Body weight,"At baseline, during clinical visits and based on clinical needs. The need for dosage adjustments should be evaluated if necessary.",
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,6,Height,At the start of treatment for all (to be able to assess BMI throughout treatment) and monthly for children (to assess growth).,
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,7,Rapid molecular testing,Xpert MTB/RIF or Xpert Ultra at baseline (recommended) to ensure rapid diagnosis and exclude DR-TB. These tests cannot be used for treatment monitoring.,
WHO_TB_handbook_module4_treatment_2025,Table 1.9.1.,8,DST,"Undertaken where possible. It should be repeated for patients who do not improve clinically and radiologically, remain sputum smear and culture positive, or revert to positive after having converted.",